Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 101, Issue 4, 2000, Pages 239-243

  McMillan, S A ^a   McDonnell, G V ^a   Douglas, J P ^a   Hawkins, S A ^a,b  

^a ROYAL GROUP OF HOSPITALS   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

IgG index; Multiple sclerosis; ROC curve analysis; Sensitivity; Soluble adhesion molecules; Specificity

Indexed keywords

BIOLOGICAL MARKER; CD30 ANTIGEN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS;

EID: 0034100508     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2000.101004239.x     Document Type: Article

References (20)

1. 1. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
2. 2. Anderson M, Alvarez-Cermeño J, Bernardi G et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994; 57:897-902.
3. 3. Thompson AJ, Hutchinson M, Martin EA, Mansfield M, Whelan A, Feighery C. Suspected and clinically definite multiple sclerosis: the relationship between CSF immunoglobulins and clinical course. J Neurol Neurosurg Psychiatry 1985;48:989-94.
4. 4. McLean BN, Zeman AZJ, Barnes D, Thompson EJ. Patterns of blood-brain barrier impairment and clinical features in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56:356-60.
5. 5. Magalhàes A, de Sá J. CSF profiles in primary progressive and relapsing/remitting forms of multiple sclerosis. ECTRIMS 9th Congress Book of Abstracts 1993;74.
6. 6. Pirttilä T, Nurmikko T. CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis. Acta Neurol Scand 1995;92:468-71.
7. 7. Jongen PJH, Lamers KJB, Doesburg WH, Lemmens WAJG, Hommes OR. Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63:446-51.
8. 8. McDonnell GV, McMillan SA, Douglas JP, Droogan AG, Hawkins SA. Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis. J Neuroimmunol 1998;85:186-92.
9. 9. Rieckmann P, Nünke K, Burchhardt M et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood cerebrospinal fluid barrier. J Neuroimmunol 1993;47: 133-40.
10. 10. Tsukada N, Matsuda M, Miyagi K, Yanigisawa N. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 1993;43:2679-82.
11. 11. Droogan AG, McMillan SA, Douglas JP, Hawkins SA. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1. J Neuroimmunol 1996;64:185-91.
12. 12. McMillan SA, McDonnell GV, Douglas JP, Droogan AG, Hawkins SA. Elevated serum and CSF levels of soluble (s) CD30 during clinical remission in multiple sclerosis. Neurology 1998;51:1156-60.
13. 13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11.
14. 14. Delpech D, Lichtblau E. Étude quantitative des immunoglobulines G et de l'albumine du liquide cephalo-rachidien. Clin Chim Acta 1972;37:15-23.
15. 15. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: A fundamental tool in clinical medicine. Clin Chem 1993;39:561-77.
16. 16. Walker RWH, Weir G, Johnston MH, Thompson EJ. A rapid method for detecting oligoclonal IgG in unconcentrated CSF by agarose isoelectric focusing, transfer to cellulose nitrate and immunoperoxidase staining. J Neuroimmunol 1983;4:141-8.
17. 17. Thompson AJ, Kermode AG, MacManus DG et al. Pathogenesis of progressive multiple sclerosis. Lancet 1989;333: 1322-3.
18. 18. Thompson AJ, Kermode AG, MacManus DG et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990;300:631-4.
19. 19. Thompson AJ, Kermode AG, Wicks D et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
20. 20. Müller FAJ, Hänny PE, Wichmann W, Fierz W, Dürsteler MR. Cerebrospinal fluid immunoglobulins and multiple sclerosis. Correspondence with magnetic resonance imaging and visually evoked potential changes. Arch Neurol 1989;46:367-71.